Phase 1 Study of the Dual MDM2/MDMX Inhibitor ALRN-6924 in Pediatric Cancer
Phase of Trial: Phase I
Latest Information Update: 04 Nov 2019
Price : $35 *
At a glance
- Drugs ALRN 6924 (Primary) ; Cytarabine
- Indications Acute myeloid leukaemia; CNS cancer; Hepatoblastoma; Lymphoma; Precursor cell lymphoblastic leukaemia-lymphoma; Retinoblastoma; Rhabdoid tumour; Solid tumours
- Focus Adverse reactions
- 03 Apr 2019 Enrollment began in October 2018. Up to 69 patients will be enrolled as per trial design presented at the 110th Annual Meeting of the American Association for Cancer Research.
- 03 Apr 2019 Trial design presented at the 110th Annual Meeting of the American Association for Cancer Research
- 01 Nov 2018 According to an Aileron Therapeutics media release, this trial is being conducted under and agreement between the company and the Dana-Farber/Boston Children's Cancer and Blood Disorders Center.